

GERON CORPORATION  
Form 8-K  
August 22, 2001  
Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549  

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**August 13, 2001**  
**Date of Report (Date of earliest event reported)**  

---

**GERON CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)  
**230 Constitution Drive**  
**Menlo Park, California**  
(Address of principal executive  
offices) **94025**  
(Zip Code)

**0-20859**  
(Commission File Number)

**75-2287752**  
(IRS Employer  
Identification Number)

**(650) 473-7700**  
(Registrant's telephone number, including area code)

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

---

**TABLE OF CONTENTS**

Item 5. Other Events.  
Item 7. Exhibits.  
**SIGNATURES**  
**EXHIBIT INDEX**  
**EXHIBIT 99.1**

---

Table of Contents

Item 5. Other Events.

Table of Contents

## Edgar Filing: GERON CORPORATION - Form 8-K

On August 13, 2001, the Registrant publicly disseminated a press release and backgrounder announcing that Kyowo HAKKO Kogyo Co., Ltd. had selected a telomerase inhibitor compound for the treatment of cancer. The compound (GRN163) is a short, modified oligonucleotide designed as a telomerase template antagonist. The compound shows good bioavailability and binds specifically to the active site of telomerase, thereby blocking its activity in cancer cells.

The foregoing description is qualified in its entirety by reference to the Registrant's Press Release and Backgrounder dated August 13, 2001, copies of which are attached hereto as Exhibit 99.1.

### Item 7. Exhibits.

Exhibits

99.1 Press Release and Backgrounder dated August 13, 2001.

2

---

### Table of Contents

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GERON CORPORATION

Date: August 22, 2001

By: /s/ David L. Greenwood

Name: David L. Greenwood

Title: Senior Vice President and Chief Financial Officer

3

---

### Table of Contents

#### EXHIBIT INDEX

Exhibits

99.1 Press Release and Backgrounder dated August 13, 2001.